Associated Papers
Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.
Varadarajan K et al.
Molecular Cancer Therapeutics, 2025
40300249 (PubMed )
Supplement: mct-24-0884_supplementary_table_2_suppst2.pdf
Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis.
Dong J et al.
Journal of Ovarian Research, 2024
38937827 (PubMed )
Supplement: 13048_2024_1455_MOESM7_ESM.xlsx › Table_S2
Discovering Deleterious Single Nucleotide Polymorphisms of Human AKT1 Oncogene: An In Silico Study.
Zhang R et al.
Life (basel, Switzerland), 2023
37511907 (PubMed )
Supplement: life-13-01532-s001.zip › Supplementary_Table_S2.pdf
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P et al.
Frontiers in Oncology, 2023
36910641 (PubMed )
Supplement: DataSheet_1.xlsx › Table_S8
AKT mutant allele-specific activation dictates pharmacologic sensitivities.
Shrestha Bhattarai T et al.
Nature Communications, 2022
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.
McAuliffe PF et al.
Plos One, 2015
26325287 (PubMed )
Supplement: pone.0136851.s006.xlsx › 006
Select a paper to view details